Characteristics | M12 | M24 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Aného (AN) | Kpalimé (KP) | Atakpamé (AT) | Kara (KA) | Total | Aného (AN) | Kouvé (KO) | Kpalimé (KP) | Atakpamé (AT) | Kara (KA) | Total | |
Number of patients (n) | 19 | 14 | 26 | 43 | 102 | 58 | 103 | 37 | 50 | 37 | 285 |
Women (%) | 17 (89.5 %) | 13 (92.8 %) | 20 (76.9 %) | 34 (79.1 %) | 84 (82.4 %) | 42 (72.4 %) | 74 (71.9 %) | 26 (70.3 %) | 39 (78.0 %) | 24 (64.9 %) | 205 (71.9 %) |
Median age years (IQR) | 42 (35–51) | 38 (36–49) | 35 (33–42) | 36 (31–40) | 36 (31–42) | 40 (35–44) | 38 (32–45) | 40 (34–46) | 36 (30–46) | 37 (33–42) | 39 (33–45) |
WHO stages | |||||||||||
1/2 | 2/19 (10.5 %) | 9/14 (64.3 %) | 15/24 (62.5 %) | 20/42 (47.6 %) | 46/99 (46.4 %) | 13/58 (22.4 %) | 24/102 (23.5 %) | 18/34 (52.9 %) | 39/43 (90.7 %) | 13/37 (35.1 %) | 107/274 (39.1 %) |
3/4 | 17/19 (89.5 %) | 5/14 (35.7 %) | 9/24 (37.5 %) | 22/42 (52.4 %) | 53/99 (53.6 %) | 45/58 (77.6 %) | 78/102 (76.5 %) | 16/34 (47.1 %) | 4/43 (9.3 %) | 24/37 (64.9 %) | 167/274 (60.9 %) |
CD4 counts available at baseline (n) | 18 (94.7 %) | 14 (100 %) | 26 (100 %) | 43 (100 %) | 101 (99.0 %) | 56/58 (96.6 %) | 103/103 (100 %) | 31/37 (83.8 %) | 42/50 (84 %) | 35/37 (94.6 %) | 667/285 (93.7 %) |
Median CD4 counts at baseline (IQR) | 107 (86–181) | 109 (71–235) | 197 (111–277) | 202 (101–274) | 176 (86–261) | 134 (110–210) | 154 (75–232) | 120 (80–158) | 201 (167–242) | 135 (106–185) | 152 (88–219) |
First line drugs n (%) | |||||||||||
AZT-3TC-EFV | 1 (5.3 %) | – | 1 (3.8 %) | 1 (2.3 %) | 3 (2.9 %) | 1 (1.7 %) | 6 (5.8 %) | 2 (5.4 %) | 10 (20.0 %) | 3 (8.1 %) | 23 (8.1 %) |
AZT-3TC-NVP | 1 (5.3 %) | – | 10 (23.3 %) | 11 (10.8 %) | 7 (12.1 %) | – | – | 6 (12.0 %) | – | 13 (4.6 %) | |
AZT-3TC-NVP/EFV | – | – | – | – | – | – | 2 (1.9 %) | – | – | – | 2 (0.7 %) |
D4T-3TC-NVP | 1 (5.3 %) | 5 (35.7 %) | 7 (26.9 %) | 2 (4.7 %) | 15 (14.7 %) | 4 (6.9 %) | 3 (2.9 %) | – | 1 (2.0 %) | 1 (2.7 %) | 9 (3.2 %) |
D4T/AZT-3TC-NVP | 16 (84.2 %) | 7 (20.0) | 15 (57.7 %) | 28 (65.1 %) | 66 (64.7 %) | 43 (75.8 %) | 86 (83.5 %) | 32 (86.5 %) | 32 (64.0 %) | 33 (89.2 %) | 226 (79.3 %) |
D4T/AZT-3TC-NVP/EFV | – | 2 (10.0 %) | 1 (3.8 %) | 3 (2.9 %) | 3 (5.2 %) | 1 (0.98 %) | 3 (8.1 %) | – | – | 7 (2.5 %) | |
D4T/AZT/TDF-3TC-NVP/EFV | – | – | 1 (3.8 %) | 1 (2.3 %) | 2 (1.9 %) | – | 2 (1.9 %) | – | – | – | 2 (0.7 %) |
TDF-3TC-AZT | – | – | – | – | – | – | 1 (0.98 %) | – | – | – | 1 (0.3 %) |
TDF-3TC-NVP | – | – | 1 (3.8 %) | – | 1 (0.99 %) | – | – | – | – | – | – |
AZT/TDF-3TC-NVP/EFV | – | – | – | 1 (2.3 %) | 1 (0.99 %) | – | – | – | – | – | – |
D4T/AZT/TDF-3TC-EFV | – | – | – | – | – | – | 1 (0.98 %) | – | – | – | 1 (0.3 %) |
AZT/TDF-3TC-EFV | – | – | – | – | – | – | 1 (0.98 %) | – | – | – | 1 (0.3 %) |
VL >1000 copies/ml n (%) | 6/19 (31.6 %) | 3/14 (23.1 %) | 5/26 (19.2 %) | 6/43 (13.9 %) | 20/102 (19.6 %) | 13/58 (22.4 %) | 14/103 (13.6 %) | 11/37 (29.7 %) | 9/50 (18.0 %) | 3/37 (8.1 %) | 50/285 (17.5 %) |
Obtained pol sequences (n/n tested) | 6/6 | 3/3 | 5/5 | 6/6 | 20/20 | 12/13 | 14/14 | 10/11 | 8/9 | 3/3 | 47/50 |
Frequency of drug resistant HIV (n/n tested) | 6/6 | 3/3 | 5/5 | 6/6 | 20/20 | 12/12 | 13/14 | 10/10 | 7/8 | 3/3 | 45/47 |
NRTI only | 0 | 0 | 0 | 0 | 0/20 | 0 | 0 | 1 | 1 | 0 | 2 |
NNRTI only | 0 | 0 | 0 | 0 | 0/20 | 3 | 1 | 0 | 0 | 0 | 4 |
NRTI + NNRTI | 6 | 3 | 5 | 6 | 20/20 | 9 | 12 | 9 | 6 | 3 | 39 |
Global drug resistance n (%) | 6/19 (31.6 %) | 3/14 (23.1 %) | 5/26 (19.2 %) | 6/43 (13.9 %) | 20/102 (19.6 %) | 12/58 (20.7 %) | 13/103 (12.6 %) | 10/37 (27.0 %) | 7/50 (14.0 %) | 3/37 (8.1 %) | 45/285 (15.8 %) |
Resistance to 2 drugs of first line ART | 4 | 3 | 3 | 2 | 12/20 | 2 | 6 | 5 | 2 | 0 | 15/45 |
Resistance to 3 drugs of first line ART | 2 | 0 | 2 | 4 | 8/20 | 7 | 6 | 5 | 4 | 3 | 25/45 |
Cross-resistance to second line NNRTI | |||||||||||
ETV | 1 | 0 | 1 | 1 | 3/20 | 3 | 3 | 3 | 1 | 1 | 11/45 |
RPV | 3 | 1 | 3 | 6 | 13/20 | 9 | 8 | 6 | 5 | 3 | 31/45 |
Cross-resistance to other NRTIs | |||||||||||
ABC | 2(I) | 0 | 2 | 1 | 3/20 | 2 | 1 | 3 | 1 | 2 | 9/45 |
DDI | 0 | 0 | 1 | 0 | 1/20 | 2 | 0 | 0 | 0 | 0 | 2/45 |
TDF | 0 | 0 | 1 | 0 | 1/20 | 1 | 1 | 0 | 0 | 0 | 2/45 |